about
Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR.Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.Human cerebral neuropathology of Type 2 diabetes mellitusEffect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both.Increased insulin sensitivity and reduced micro and macro vascular disease induced by 2-deoxy-D-glucose during metabolic syndrome in obese JCR: LA-cp rats.Thiazolidinediones: effects on insulin resistance and the cardiovascular system.Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension.PPARgamma and MEK Interactions in CancerPPARs and the kidney in metabolic syndrome.Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathwayDHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells.The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9.Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formationAcute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation.Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease.PPARγ and NAD(P)H oxidase system interaction in glycerol-induced acute renal failure: role of gp91phox subunit of NAD(P)H oxidase.Peroxisome proliferator-activated receptor γ agonists attenuate hyperglycaemia-induced hyaluronan secretion in vascular smooth muscle cells by inhibiting PKCβ2.Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
P2860
Q33440398-3F80B44B-0450-458F-8911-5143E3AF3899Q33554780-80483EF2-0AB7-4970-B023-CF682C36C023Q33642252-AD826648-5516-4A77-B642-5233FE78C860Q33710643-3D73B92A-2D17-49D4-93FB-BFA207201414Q35754155-860B2695-70FD-4D29-8091-EFB88E0FC8FAQ36052731-D700AF1E-4E00-4E50-B043-5E645EFDCC1CQ36484662-3FD2D6C0-E51A-428B-9EA7-3676339A5458Q36509300-D75CB2F7-BEF4-4DDB-B54E-E294060E9084Q36737285-63E720BD-CD05-43CD-9EC8-791B9582C8D9Q37072216-CE3DE98B-4998-4F72-9489-EBDDDB472DE8Q37141708-106058C1-144D-4A4D-9082-60FB47F6AC93Q37398399-E39CC3EB-11A2-47EB-83E5-0ABCC4B63F49Q41817555-90C477A3-F067-413B-984C-BDD1CBF822A5Q41932068-B769DD44-0EF4-4F5D-AE88-C9CE60D6DA16Q43042437-6B78FC0B-7117-49F3-8B70-428728DC9330Q46069799-4D2CDC2B-0C3A-4BB0-BA27-DD4D5BCE4898Q46938734-09E430C9-53DA-45DA-ABAE-D634EC834E94Q54444900-436A6D0F-AA51-45F7-AADF-447628755071Q55397745-C141CF0D-4C93-4613-969B-ABD4065B9EA7
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vascular effects of TZDs: new implications.
@ast
Vascular effects of TZDs: new implications.
@en
Vascular effects of TZDs: new implications.
@nl
type
label
Vascular effects of TZDs: new implications.
@ast
Vascular effects of TZDs: new implications.
@en
Vascular effects of TZDs: new implications.
@nl
prefLabel
Vascular effects of TZDs: new implications.
@ast
Vascular effects of TZDs: new implications.
@en
Vascular effects of TZDs: new implications.
@nl
P2093
P1476
Vascular effects of TZDs: new implications.
@en
P2093
Florian Blaschke
Mehmood Khan
Robert Spanheimer
Ronald E Law
P356
10.1016/J.VPH.2005.11.009
P577
2006-06-05T00:00:00Z